ALVAL On Other Exchanges
Symbol
Exchange
EN Paris

valbiotis sas (ALVAL) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALBIOTIS SAS (ALVAL)
\

Related News

No related news articles were found.

valbiotis sas (ALVAL) Related Businessweek News

No Related Businessweek News Found

valbiotis sas (ALVAL) Details

Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for the treatment of type 2 diabetes. The company also develops VAL-63, a health supplement that is used for the prevention of non-alcoholic fatty liver disease; and VAL-630, a medical nutrition product for providing nutritional support for patients with non-alcoholic steatohepatitis and type 2 diabetes. In addition, the company’s products under clinical development comprise Lipidrive that regulates body weight by acting specifically on body fat mass; and VAL-070, which reduces lipid dysfunctions cholesterol, a risk factor for cardiovascular disease. Valbiotis SA was founded in 2014 and is based in Périgny, France.

38 Employees
Last Reported Date: 03/8/19
Founded in 2014

valbiotis sas (ALVAL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

valbiotis sas
VALBIOTIS Announces Completion of the International Phase IIA Clinical Study Evaluating VALEDIA

VALBIOTIS announced the completion of the international Phase IIA clinical study evaluating VALEDIA in prediabetic subjects, after the final follow-up visit was conducted with the last patient. VALBIOTIS will present the results of this study before 31 July 2019. The international Phase IIA, multicentric study was randomized, double-blind placebo-controlled, and included 66 prediabetic subjects. The study evaluates the efficacy of TOTUM-63, the active ingredient of VALEDIA, in reducing one or more of the 3 risk factors for type 2 diabetes, from the 3 criteria chosen by the Food and Drug Administration to obtain a healthclaim: insulin resistance, moderate fasting hyperglycemia and glucose intolerance. In addition to these prediabetes results, the study will evaluate other physiological parameters, including, for example, triglyceride regulation or intestinal microbiota composition. This additional data will help confirm the potential of VALEDIA for other applications.

VALBIOTIS Appoints Agnès TIXIER to the Supervisory Board

VALBIOTIS announced the appointment of Agnès TIXIER to the Supervisory Board. This appointment, approved during the General Meeting on March 18, 2019. Currently Director at CM-CIC INVESTISSEMENT.

Valbiotis SA Presents at ESN European Conference, Apr-04-2019

Valbiotis SA Presents at ESN European Conference, Apr-04-2019 . Venue: Palais Brongniart, 16 Place de la Bourse, 75002, Paris, France.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ALVAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALVAL.
View Industry Companies
 

Industry Analysis

ALVAL

Industry Average

Valuation ALVAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 189.5x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 61.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VALBIOTIS SAS, please visit valbiotis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.